Trial Profile
A Two Arm Randomised, Open-label Study to Investigate the Persistence of Autoantibody Neutralisation, the Safety, and Pharmacokinetics of BC 007 in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) and Autoantibodies Directed Against the beta1 Adrenergic Receptor
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 05 Apr 2023
Price :
$35
*
At a glance
- Drugs BC 007 (Primary)
- Indications Dilated cardiomyopathy
- Focus Therapeutic Use
- Sponsors Berlin Cures
- 31 Mar 2023 Status changed from active, no longer recruiting to completed.
- 19 Jul 2022 Planned End Date changed from 1 Sep 2022 to 1 Dec 2022.
- 19 Jul 2022 Planned primary completion date changed from 1 Aug 2022 to 1 Dec 2022.